证券代码：002365 证券简称：永安药业 公告编号：2023-50 潜江永安药业股份有限公司 关于取得实用新型专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，潜江永安药业股份有限公司（以下简称"公司"）收到国家知识产权 局颁发的两项实用新型专利证书，具体内容如下： 专利一： 实用新型名称：一种生产牛磺酸的氨解装置 发明人：陈勇；方锡权；李少波 专利号：ZL 2023 2 1560409.X 专利权人：潜江永安药业股份有限公司 地址：433100 湖北省潜江市潜江经济开发区广泽大道 2 号 专利申请日：2023 年 06 月 19 日 授权公告日：2023 年 12 月 05 日 授权公告号：CN 220126187 U 专利有效期：从申请日开始 10 年 专利二： 实用新型名称：一种牛磺酸结晶釜搅拌装置 发明人：陈勇；方锡权；李少波 专利号：ZL 2023 2 1559625.2 专利权人：潜江永安药业股份有限公司 地址：433100 湖北省潜江市潜江经济开发区广泽大道 2 号 专利申请日：2023 年 06 月 19 日 授权公告日： ...

证券代码：002365 证券简称：永安药业 公告编号：2023-49 潜江永安药业股份有限公司 关于控股子公司取得实用新型专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 发明人：张勇；夏昌培；吴国雨；徐华锋；张琴；陈翔 专利号：ZL 2023 2 1115232.2 专利权人：湖北凌安科技有限公司 地址：433100 湖北省潜江经济开发区荆河源路 16 号 专利申请日：2023 年 05 月 10 日 授权公告日：2023 年 09 月 12 日 近日，潜江永安药业股份有限公司（以下简称"公司"）控股子公司湖北凌 安科技有限公司（以下简称"凌安科技"）收到国家知识产权局颁发的六项实用 新型专利证书，具体内容如下： 专利一： 实用新型名称：一种减水剂混合装置的定量加料机构 发明人：张勇；李敏；胡开志；汪新国；闵锐；刘红琼 专利号：ZL 2023 2 1299401.2 专利权人：湖北凌安科技有限公司 地址：433100 湖北省潜江经济开发区荆河源路 16 号 专利申请日：2023 年 05 月 26 日 授权公告日：2023 年 09 月 22 ...

证券代码：002365 证券简称：永安药业 公告编号：2023-48 潜江永安药业股份有限公司 关于取得美国专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，潜江永安药业股份有限公司（以下简称"公司"）收到美国专利商标 局颁发的一项专利证书，具体内容如下: 专利发明的名称：一种制备牛磺酸的方法 专利申请日：2021 年 08 月 16 日 专利公告日：2023 年 10 月 03 日 专利权人：潜江永安药业股份有限公司，中国湖北省 发明人：陈勇、方锡权、李少波、刘锋 专利有效期：从申请日开始 20 年 本次取得的美国专利证书与 2023 年中国国家知识产权局颁发的发明专利证 书《一种制备牛磺酸的方法》（《关于取得发明专利证书的公告》公告编号：2023-08） 及 2022 年日本专利局颁发的专利证书《一种制备牛磺酸的方法》（《关于取得 日本专利证书的公告》公告编号：2022-21）同为一种方法。 公司为全球牛磺酸领域的知名企业，一直致力于牛磺酸生产技术的研发，该 专利的取得有利于保护和发挥公司主导产品自主知识产权优势，使公司继续在 牛磺酸领 ...

Financial Performance - The company's revenue for Q3 2023 was ¥224,380,663.07, a decrease of 24.25% compared to the same period last year[5] - The net profit attributable to shareholders was -¥9,698,703.80, reflecting a decline of 121.52% year-on-year[5] - The net profit after deducting non-recurring gains and losses was -¥21,785,696.79, a decrease of 161.45% compared to the previous year[5] - The basic earnings per share were -¥0.03, a decline of 120.00% compared to the same period last year[5] - Operating profit decreased by 58.18% to CNY 179.53 million due to a decline in the sales price of main products[10] - Total profit fell by 59.98% to CNY 71.25 million, primarily due to the decrease in operating profit[10] - Net profit decreased by 73.46% to CNY 41.09 million, attributed to the decline in total profit[10] - Total operating revenue for Q3 2023 was CNY 802,818,715.84, a decrease of 28.5% compared to CNY 1,123,122,060.94 in the same period last year[20] - Net profit for Q3 2023 was CNY 41,086,189.05, a decline of 73.5% compared to CNY 154,787,504.15 in Q3 2022[21] - The total comprehensive income for the period attributable to the parent company was CNY 49,540,757.47, compared to CNY 167,568,822.48 in the previous period, representing a decrease of approximately 70.5%[22] - Basic and diluted earnings per share for the current period were CNY 0.16, down from CNY 0.55 in the previous period, reflecting a decline of about 72.7%[22] Cash Flow and Investments - The operating cash flow for the year-to-date period was ¥194,396,155.83, down 27.82% from the previous year[5] - Cash flow from investment activities improved by 35.83%, with a net outflow of CNY 160.65 million, mainly due to a reduction in financial management scale[10] - Cash flow from financing activities showed a significant increase of 540.38%, with a net outflow of CNY 67.19 million, primarily due to dividend payments and bank loan repayments[10] - The company's cash and cash equivalents increased to CNY 275,995,419.71 from CNY 274,716,138.81 at the beginning of the year[18] - Accounts receivable decreased to CNY 153,276,487.64 from CNY 172,942,083.99 at the beginning of the year, indicating improved cash flow management[18] - The total cash inflow from operating activities was CNY 941,698,332.49, down 31.9% from CNY 1,381,813,769.42 in the previous period[24] - Cash inflow from investment activities totaled CNY 1,024,139,212.78, compared to CNY 634,014,240.39 in the previous period, indicating an increase of approximately 61.5%[25] - The net cash flow from investment activities was -CNY 160,648,157.01, an improvement from -CNY 250,340,254.71 in the previous period[25] - Cash and cash equivalents at the end of the period amounted to CNY 245,795,419.71, compared to CNY 108,963,400.62 at the end of the previous period, showing an increase of about 125.5%[25] - The company reported cash outflows from financing activities of CNY 77,190,569.53, up from CNY 41,492,232.43 in the previous period, representing an increase of approximately 86.0%[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,425,297,475.95, a slight increase of 0.05% from the end of the previous year[5] - The total assets of the company as of September 30, 2023, were CNY 2,425,297,475.95, slightly up from CNY 2,424,179,175.81 at the beginning of the year[18] - The total liabilities decreased to CNY 306,573,924.47 from CNY 321,173,058.41, showing a reduction in financial leverage[18] - The company's retained earnings increased to CNY 871,429,068.58 from CNY 854,469,697.68, indicating a positive trend in profit retention[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 29,842[12] - The largest shareholder, Chen Yong, holds 21.54% of the shares, amounting to 63.47 million shares[12] - The company completed a capital increase for its subsidiary, Ling'an Chemical, raising its registered capital from CNY 1 million to CNY 5 million[15] Operational Developments - The company reported a significant increase in accounts receivable financing, rising by 159.90% to ¥12,343,096.24 due to increased supply chain financing[9] - Inventory decreased by 45.20% to ¥81,976,665.93 as a result of product repurchase agreements[9] - The company recognized government subsidies amounting to ¥4,883,571.80 during the reporting period, contributing to non-recurring gains[6] - The company is actively responding to a patent infringement lawsuit in the U.S., with a favorable ruling regarding certain patents[14] - The company is expanding its production capacity for taurine food additives, with a project budget of CNY 250 million currently under construction[14] Audit and Compliance - The company did not undergo an audit for the third quarter report[26]

关于高级管理人员退休辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002365 证券简称：永安药业 公告编号：2023-47 潜江永安药业股份有限公司 二○二三年十月二十六日 近日，潜江永安药业股份有限公司（以下简称"公司"）董事会收到高级管 理人员梅松林先生的书面辞职报告，梅松林先生因到龄退休，申请辞去公司供应 部部长和高级管理人员的职务，辞职后将不再担任公司任何职务。梅松林先生所 负责的相关工作已进行了交接，其辞职不会影响公司正常生产经营活动。根据《公 司法》《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》 等有关规定，梅松林先生辞职报告自送达董事会时生效。 截至本公告披露日，梅松林先生持有公司股票 190,000 股，占公司总股本的 0.06%，梅松林先生离任后，其所持股份将严格按照《深圳证券交易所上市公司 自律监管指引第 10 号——股份变动管理》《深圳证券交易所上市公司股东及董 事、监事、高级管理人员减持股份实施细则》等法律、法规的相关规定进行管理。 梅松林先生在任职期间，恪尽职守，勤勉尽责，公司及董事会 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）于 2023 年 5 月 23 日召开 第六届董事会第十六次会议，审议通过了《关于使用自有资金进行委托理财的议 案》，同意公司及子公司总计使用最高额度不超过（含）人民币 7 亿元的自有资 金进行委托理财。上述额度可滚动使用，有效期自董事会审议通过之日起不超过 12 个月，并授权公司管理层具体实施相关事宜。公司根据上述决议，择机购买 了相关理财产品，现将有关情况公告如下： 证券代码：002365 证券简称：永安药业 公告编号：2023-45 潜江永安药业股份有限公司 关于购买理财产品的进展公告 一、理财产品的主要情况 （一）2023 年 10 月 18 日，公司出资 3000 万元，向中国银河证券股份有限 公司（以下简称"银河证券"）购买理财产品，具体情况如下： 1、产品名称：银河盛汇尊享 3 号集合资产管理计划 2、产品代码：ZX1003 3、产品主要投资范围： 本集合计划仅投资于标准化资产，具体包括： （1）固定收益类资产：现金、货币市场基金、银行存款、大额存单、同业 ...

证券代码：002365 证券简称：永安药业 公告编号：2023-44 潜江永安药业股份有限公司 关于取得印度尼西亚专利证书的公告 专利号码：IDP000088588 专利备案日期：2020 年 12 月 15 日 专利授权日期：2023 年 07 月 18 日 发明人：陈勇、方锡权、李少波、刘锋 申请人及地址：潜江永安药业股份有限公司 中国湖北省潜江市广泽大道 2 号 433100 专利有效期：从申请日开始 20 年 本次取得的专利证书与 2023 年美国专利商标局颁发的发明专利证书《一种 制备高纯度牛磺酸和盐的方法和系统》（《关于取得美国发明专利证书的公告》 公告编号：2023-10）及 2022 年日本专利局颁发的专利证书《一种制备高纯度 牛磺酸和盐的方法和系统》（《关于取得日本专利证书的公告》公告编号：2022-34）、 中国国家知识产权局颁发的发明专利证书《一种制备高纯度牛磺酸和盐的方法和 系统》（《关于取得发明专利证书的公告》公告编号：2022-44）、欧洲专利局 颁发的专利证书《一种制备高纯度牛磺酸和盐的方法和系统》（《关于取得欧洲 专利证书的公告》公告编号：2022-46）同为一种方法。 本公司 ...

近日，潜江永安药业股份有限公司（以下简称"公司"）收到国家知识产权 局颁发的一项发明专利证书，具体内容如下: 发明名称：一种牛磺酸母液回收利用的方法 证券代码：002365 证券简称：永安药业 公告编号：2023-43 潜江永安药业股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司 董 事 会 二〇二三年十月八日 专利有效期：从申请日开始 20 年 公司为全球牛磺酸领域的知名企业，一直致力于牛磺酸生产技术的研发，该 专利的取得有利于保护和发挥公司主导产品自主知识产权优势，使公司继续在 牛磺酸领域保持技术领先优势,有利于提升公司的核心竞争力，进一步提高公司 牛磺酸产品在国际市场的知名度。该专利的取得暂不会对公司生产经营和业绩 产生重大影响。 特此公告。 发明人：陈勇；方锡权；李少波；刘锋 专利号：ZL 2021 1 1602226.5 专利权人：潜江永安药业股份有限公司 地址：433100 湖北省潜江市潜江经济开发区广泽大道 2 号 专利申请日：2021 年 12 月 24 日 授权公告日：2023 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥578,438,052.77, a decrease of 30.05% compared to ¥826,907,037.44 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥56,126,324.70, down 51.86% from ¥116,592,224.01 year-on-year[20]. - The net profit after deducting non-recurring gains and losses was ¥12,164,917.17, a significant decline of 88.82% compared to ¥108,783,673.06 in the previous year[20]. - Basic and diluted earnings per share were both ¥0.19, down 52.50% from ¥0.40 in the previous year[20]. - Operating profit for the same period was ¥73,493,727.55, down 43.84% year-on-year[38]. - The company’s earnings per share decreased by 52.50% to ¥0.19[38]. - The company reported a total revenue of ¥578,438,052.77 for the first half of 2023, a decrease of 30.05% compared to the same period last year[45]. - The revenue from taurine was 309,893,968.83 CNY, down 42.95% year-on-year, but showed a 22.21% increase compared to the second half of 2022[39]. - The health supplement segment, Yong'an Health, achieved a revenue of 173,470,791.52 CNY, representing a growth of 44.63% year-on-year, with a net profit increase of 303.38% to 46,931,745.92 CNY[40]. Cash Flow and Investments - The net cash flow from operating activities increased by 18.58% to ¥159,111,289.83 from ¥134,178,943.01 in the same period last year[20]. - The company’s cash flow from operating activities increased by 18.58% to 159,111,289.83 CNY, indicating improved operational efficiency[45]. - The company’s net cash and cash equivalents decreased by 116.39% to -20,387,794.36 CNY, primarily due to increased investments and project expenditures[45]. - The company reported an investment income of ¥8,785,902.22, accounting for 13.31% of total profit, primarily from the disposal of trading financial assets[51]. - The total investment during the reporting period was ¥95,153,966.61, a substantial increase of 1,617.04% compared to the previous year[56]. - The company reported a significant increase in other revenue, which rose by 190.83% to ¥72,804,156.03[48]. - The company has a total of CNY 72,241.85 million in entrusted financial management, with an outstanding balance of CNY 60,080.3 million[120]. Market Position and Business Segments - The company holds a 50% market share in the taurine industry, with an annual production capacity of 58,000 tons, making it the largest producer globally[28]. - The company is involved in four main business areas, including taurine, epoxy ethane, polycarboxylate superplasticizers, and health food products[32]. - The health food market in China is growing, driven by rising consumer awareness and an aging population, presenting significant market opportunities[31]. - The company is focusing on expanding its domestic market presence and actively participating in international trade fairs to explore new markets[38]. - The company is focusing on cash management and investments in health-related sectors to optimize its financial resources[32]. Risks and Compliance - The company faces various risks including safety, environmental, operational, exchange rate, and management risks[4]. - The company is exposed to exchange rate risks as a significant portion of revenue is settled in USD, leading to potential foreign exchange losses[73]. - The company is committed to ensuring the safety and compliance of its chemical products, particularly those that may contain hazardous materials[58]. - The company has obtained environmental assessments and permits for its production lines, ensuring compliance with environmental regulations[84]. - The company has made significant investments in environmental protection, including costs for flue gas desulfurization and denitrification facilities, and hazardous waste disposal[87]. Corporate Governance and Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has fulfilled all commitments made by its actual controllers, shareholders, and related parties during the reporting period[96]. - There are no non-operating fund occupations by controlling shareholders or other related parties during the reporting period[98]. - The company has not engaged in any violations regarding external guarantees during the reporting period[99]. - The total number of common shareholders at the end of the reporting period is 29,878[135]. - The largest shareholder, Chen Yong, holds 21.54% of the shares, totaling 63,468,000 shares[135]. Research and Development - Research and development investment increased by 8.14% to 22,743,920.27 CNY, reflecting the company's commitment to innovation[45]. - The company is focused on research and development of new products, aiming to enhance its competitive edge in the pharmaceutical industry[181]. Legal Matters - The company is involved in ongoing patent litigation in the U.S. regarding its taurine production process, with a favorable ruling on June 9, 2023, affirming that its process does not infringe on the specified patents[103]. - The company has a total of 5 ongoing lawsuits, with a total amount involved of approximately 1,374,600 RMB (137.46 million RMB) in litigation claims[103].

证券代码：002365 证券简称：永安药业 公告编号：2023-41 潜江永安药业股份有限公司 关于购买理财产品的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）于 2023 年 5 月 23 日召开 第六届董事会第十六次会议，审议通过了《关于使用自有资金进行委托理财的议 案》，同意公司及子公司总计使用最高额度不超过（含）人民币 7 亿元的自有资 金进行委托理财。上述额度可滚动使用，有效期自董事会审议通过之日起不超过 12 个月，并授权公司管理层具体实施相关事宜。公司根据上述决议，择机购买 了相关理财产品，现将有关情况公告如下： 一、理财产品的主要情况 （一）2023 年 8 月 8 日，公司出资 3000 万元，向中信证券股份有限公司（以 下简称"中信证券"）购买理财产品，具体情况如下： 1、产品名称：中信期货-粤湾 2 号集合资产管理计划 2、产品代码：SQP397 3、产品主要投资范围： （1）在银行间市场和交易所市场交易的国债、金融债、地方政府债、央行 票据、企业债券、公司债、资产支持证券、资产支持 ...